文献速递血液净化与透析水电解质与酸碱

口服托伐普坦在血液透析患者中的疗效与安全性:2期双盲随机安慰剂对照试验

Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

这项2期双盲随机安慰剂对照试验纳入124例每周三次血液透析且24小时尿量≥500 mL的日本患者,随机接受托伐普坦15 mg/日、30 mg/日或安慰剂治疗24周。主要发现托伐普坦显著增加24小时尿量,但未显著改善每周透析总脱水量和透析间期体重增加,安全性总体可耐受。

要点

  • 托伐普坦15 mg/日和30 mg/日均显著增加24小时尿量。
  • 托伐普坦未显著减少每周透析总脱水量和透析间期体重增加。
  • 托伐普坦组治疗中出现的不良事件比例高于安慰剂组。

核心结论

  • 托伐普坦在血液透析患者中维持利尿作用24周,但未同等程度减少每周透析总脱水量和透析间期体重增加。

研究设计与样本

  • 随机、双盲、安慰剂对照的2期试验,纳入124例每周三次血液透析且24小时尿量≥500 mL的日本患者。
  • 患者随机接受口服托伐普坦15 mg/日(n=40)、30 mg/日(n=40)或安慰剂(n=44)治疗24周。

主要发现

  • 治疗结束时,24小时尿量较基线变化的组间差值:托伐普坦15 mg组为429.1 mL(95%CI 231.0–627.2;P<0.0001),30 mg组为371.6 mL(95%CI 144.1–599.2;P=0.0017)。
  • 每周透析总脱水量和透析间期体重增加较基线变化在托伐普坦组与安慰剂组间无显著差异。
  • 治疗中出现不良事件的患者比例:安慰剂组77.3%,托伐普坦组92.3%。

临床怎么用

  • 对于24小时尿量≥500 mL的血液透析患者,托伐普坦可增加尿量,但未显示减少透析间期体重增加或透析总脱水量。
  • 使用托伐普坦时需关注治疗中出现的不良事件。

局限性

  • 研究人群为日本血液透析患者,24小时尿量≥500 mL,结果外推需谨慎。
  • 样本量124例,为2期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Loop diuretics are used to manage fluid retention in patients with end-stage kidney disease undergoing hemodialysis (HD). This randomized, double-blind, placebo-controlled, Phase 2 trial evaluated the efficacy and safety of tolvaptan, a vasopressin V2 receptor antagonist, in Japanese HD patients. METHODS: A total of 124 patients (24-h urine volume ≥500 mL) on thrice-weekly HD were randomized to receive oral tolvaptan 15 mg/day (n = 40), tolvaptan 30 mg/day (n = 40) or placebo (n = 44) for 24 weeks. Efficacy endpoints were change from baseline in 24-h urine volume, total fluid removal by HD per week and interdialytic weight gain (IDWG). Safety was assessed via the incidence of treatment-emergent adverse events (TEAEs). RESULTS: At treatment end, the difference (95% confidence interval) from the placebo group in the mean change from baseline in 24-h urine volume was significant in the tolvaptan 15 mg {429.1 mL [95% confidence interval (CI) 231.0, 627.2]; P < 0.0001} and 30 mg [371.6 mL (95% CI 144.1, 599.2); P = 0.0017] groups. The mean changes from baseline in total fluid removal by HD and IDWG were not significantly different in the tolvaptan groups versus the placebo group. Although the proportion of patients with TEAEs was lower in the placebo group (77.3%) than in the tolvaptan groups (92.3%), tolvaptan was safe and well-tolerated during the study period. CONCLUSIONS: Tolvaptan significantly sustained diuretic action for 24 weeks in HD patients but did not reduce total fluid removal by HD per week and IDWG to the same extent.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ogata H, Shimofurutani N, Okada T, et al. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial. Nephrol Dial Transplant. 2021. PMID: 32901255. doi:10.1093/ndt/gfaa148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。